Literature DB >> 28125785

CT Colonographic Screening of Patients With a Family History of Colorectal Cancer: Comparison With Adults at Average Risk and Implications for Guidelines.

Perry J Pickhardt1, Ifeanyi Mbah1, B Dustin Pooler1, Oliver T Chen1, J Louis Hinshaw1, Jennifer M Weiss1, David H Kim1.   

Abstract

OBJECTIVE: The purposes of this study were to compare rates of lesion detection at CT colonographic (CTC) screening of adults without symptoms who had and who did not have a family history of colorectal cancer according to American Cancer Society guidelines and to consider the clinical implications.
MATERIALS AND METHODS: Over 134 months, consecutively registered CTC cohorts of adults without symptoms who had (n = 156; 88 [56.4%] women; 68 [43.6%] men; mean age, 56.3 years) and who did not have (n = 8857; 4757 [53.7%] women; 4100 [46.3%] men; mean age, 56.6 years) an American Cancer Society-defined family history of colorectal cancer (first-degree relative with diagnosis before age 60 years or two first-degree relatives with diagnosis at any age) were compared for relevant colorectal findings.
RESULTS: For the family history versus no family history cohorts, the frequency of all nondiminutive polyps (≥ 6 mm) reported at CTC was 23.7% versus 15.5% (p = 0.007); small polyps (6-9 mm), 13.5% versus 9.1% (p = 0.068); and large polyps (≥ 10 mm), 10.2% versus 6.5% (p = 0.068). The rate of referral for colonoscopy was greater for the family history cohort (16.0% vs 10.5%; p = 0.035). However, the frequencies of proven advanced adenoma (4.5% vs 3.2%; p = 0.357), nonadvanced adenoma (5.1% vs 2.6%; p = 0.070), and cancer (0.0% vs 0.4%; p = 0.999) were not significantly increased. The difference in positive rates between the two cohorts (11.5% vs 4.3%; p < 0.001) was primarily due to nonneoplastic findings of no colorectal cancer relevance, such as small hyperplastic polyps, diverticular disease, and false-positive CTC findings.
CONCLUSION: Although the overall CTC-positive and colonoscopy referral rates were higher in the family history cohort, the clinically relevant frequencies of advanced neoplasia and cancer were not sufficiently increased to preclude CTC screening. These findings support the use of CTC as a front-line screening option in adults with a family history of colorectal cancer.

Entities:  

Keywords:  CT colonography; colorectal cancer; family history; screening; virtual colonoscopy

Mesh:

Year:  2017        PMID: 28125785      PMCID: PMC5554009          DOI: 10.2214/AJR.16.16724

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  48 in total

1.  The effect of diagnostic confidence on the probability of optical colonoscopic confirmation of potential polyps detected on CT colonography: prospective assessment in 1,339 asymptomatic adults.

Authors:  Perry J Pickhardt; J Richard Choi; Pamela A Nugent; William R Schindler
Journal:  AJR Am J Roentgenol       Date:  2004-12       Impact factor: 3.959

2.  Carpet lesions detected at CT colonography: clinical, imaging, and pathologic features.

Authors:  Perry J Pickhardt; Vu P Lam; Jennifer M Weiss; Gregory D Kennedy; David H Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

3.  Screening CT colonography: how I do it.

Authors:  Perry J Pickhardt
Journal:  AJR Am J Roentgenol       Date:  2007-08       Impact factor: 3.959

4.  Flat (nonpolypoid) colorectal lesions identified at CT colonography in a U.S. screening population.

Authors:  Perry J Pickhardt; David H Kim; Jessica B Robbins
Journal:  Acad Radiol       Date:  2010-03-15       Impact factor: 3.173

5.  Impact of a family history of colorectal cancer on the prevalence of advanced neoplasia at colonoscopy in 4,967 asymptomatic patients.

Authors:  Franklin C Tsai; Williamson B Strum
Journal:  Dig Dis Sci       Date:  2011-12-20       Impact factor: 3.199

6.  Serrated Polyps at CT Colonography: Prevalence and Characteristics of the Serrated Polyp Spectrum.

Authors:  David H Kim; Kristina A Matkowskyj; Meghan G Lubner; J Louis Hinshaw; Alejandro Munoz Del Rio; B Dustin Pooler; Jennifer M Weiss; Perry J Pickhardt
Journal:  Radiology       Date:  2016-02-15       Impact factor: 11.105

Review 7.  Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis.

Authors:  Perry J Pickhardt; Cesare Hassan; Steve Halligan; Riccardo Marmo
Journal:  Radiology       Date:  2011-03-17       Impact factor: 11.105

8.  Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history.

Authors:  Perry J Pickhardt; David H Kim; B Dustin Pooler; J Louis Hinshaw; Duncan Barlow; Don Jensen; Mark Reichelderfer; Brooks D Cash
Journal:  Lancet Oncol       Date:  2013-06-07       Impact factor: 41.316

9.  Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis.

Authors:  Cesare Hassan; Perry J Pickhardt; Perry Pickhardt; Andrea Laghi; Daniel H Kim; Daniel Kim; Angelo Zullo; Franco Iafrate; Lorenzo Di Giulio; Sergio Morini
Journal:  Arch Intern Med       Date:  2008-04-14

10.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

View more
  2 in total

Review 1.  Evidenced-Based Screening Strategies for a Positive Family History.

Authors:  Jennifer M Kolb; Dennis J Ahnen; N Jewel Samadder
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-04-14

2.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.